Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Solara Active Pharma Sciences Limited (SOLARA.NS)
Chennai, IN
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.20% | +10.26% | +12.47% | +17.39% | -2.14% | -0.64% | +16.85% | +65.31% | -65.33% | +141.94% | +141.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.6% Q1'26: +41.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-1,300.0% Q1'26: +507.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+0.1% Q1'26: +11.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.4% Q1'26: +8.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.6% Q1'26: +6.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+14.4% Q1'26: +13.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.68× Q1'26: 2.98× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
12.68B
est: 13.36B (-5.1%)
|
15.97B
est: 16.68B (-4.3%)
|
12.68B
est: 12.68B (+0.0%)
|
14.27B
est: 14.44B (-1.2%)
|
12.89B
est: 13.00B (-0.9%)
|
12.84B
est: 15.36B (-16.4%)
|
16.81B
16.81B – 16.81B
+9.4% YoY
|
17.95B
17.95B – 17.95B
+6.8% YoY
|
| EBITDA |
2.86B
est: 989.27M (+189.0%)
|
4.14B
est: 1.49B (+177.5%)
|
793.30M
est: 1.62B (-51.0%)
|
1.52B
est: 1.72B (-11.3%)
|
-2.82B
est: 962.77M (-393.1%)
|
2.06B
est: 1.14B (+81.3%)
|
1.24B
1.24B – 1.24B
+9.4% YoY
|
1.33B
1.33B – 1.33B
+6.8% YoY
|
| EBIT |
1.93B
est: -39.64M (+4,957.9%)
|
2.85B
est: 1.79B (+58.9%)
|
-259.90M
est: 1.94B (-113.4%)
|
418.20M
est: 2.06B (-79.7%)
|
-3.85B
est: -38.58M (-9,876.1%)
|
1.07B
est: -45.59M (+2,447.7%)
|
-49.86M
-49.86M – -49.86M
-9.4% YoY
|
-53.25M
-53.25M – -53.25M
-6.8% YoY
|
| Net Income |
1.15B
est: 1.54B (-25.6%)
|
2.21B
est: 1.19B (+86.8%)
|
-581.50M
est: 1.29B (-145.2%)
|
-221.70M
est: -252.90M (+12.3%)
|
-5.67B
est: -6.04B (+6.1%)
|
5.40M
est: 686.56M (-99.2%)
|
1.25B
1.25B – 1.25B
+82.6% YoY
|
1.21B
1.21B – 1.21B
-3.4% YoY
|
| SGA |
338.50M
est: 1.61B (-78.9%)
|
648.00M
est: 3.89B (-83.3%)
|
2.39B
est: 4.22B (-43.4%)
|
2.31B
est: 4.48B (-48.5%)
|
585.10M
est: 1.56B (-62.6%)
|
2.12B
est: 1.85B (+14.6%)
|
2.02B
2.02B – 2.02B
+9.4% YoY
|
2.16B
2.16B – 2.16B
+6.8% YoY
|
| EPS |
44.29
est: 39.94 (+10.9%)
|
63.59
est: 66.07 (-3.8%)
|
-16.18
est: -14.19 (-14.0%)
|
-6.16
est: 3.84 (-260.4%)
|
-145.27
est: -156.63 (+7.3%)
|
0.14
est: 17.80 (-99.2%)
|
32.50
32.50 – 32.50
+82.6% YoY
|
31.40
31.40 – 31.40
-3.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 114.0K | 0.65% |
| 2 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 992.1K | 0.07% |
| 3 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.00% | 6.6K | 0.49% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sandeep Rao PGDM | Chief Executive Officer & MD | 33M | male |
| Ganesh Mukundan | Senior Vice President of Sales & Marketing | — | male |
| Hero Velladurai | Chief Scientific Officer | — | — |
| Mohanraj | Whole-Time Director & Chief Human Resources Officer | — | male |
| Pooja Jaya Kumar | Company Secretary & Compliance Officer | — | female |
| Raghavan Venkatramani | General Manager of Accounts | — | male |
| Rajesh Patro | Chief Risk Officer | — | male |
| Sarat Kumar | Chief Financial Officer & Chief Investor Relations Officer | — | male |
| V. Sundara Moorthy | Chief Quality Officer | — | male |
| Arun Kumar Pillai | Founder & Non-Executive Director | — | male |
| Vishal Mathur | Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SOLARA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
